NCT00086489

CP-675,206 In Patients With Advanced Melanoma

Phase 1 Open Label, Non-Randomized, Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics, Immune Function Effects, And Efficacy Of Multiple Doses Of CP-675,206 In Patients With Advanced Melanoma, And Phase 2, Open Label, Randomized Study To Evaluate the Efficacy, Safety, Tolerability And Pharmacokinetics Of 2 Regimens Of CP-675,206 In Patients With Advanced Melanoma.

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 118 (actual)
• Sponsor: AstraZeneca · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess the efficacy, safety, and tolerability of monoclonal antibody therapy using 2 regimens for the treatment of advanced melanoma

Conditions

• Malignant Melanoma

Interventions

Type	Name	Description
DRUG	CP-675,206	pts treated at 10 mg/kg dose level on a monthly regimen
DRUG	CP-675,206	pts treated at 15 mg/kg dose level on a quarterly regimen

Timeline

• Start date: 2003-08-01
• Primary completion: 2007-05-01
• Completion: 2009-05-01
• First posted: 2004-07-05
• Last updated: 2012-06-06

Locations

9 sites across 1 country: United States